Stryker Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Thanks, everybody, for joining us this morning. I am Matt Taylor, here to host the first MedTech session at the London Healthcare Conference on a nice, bright, sunny day here in London. I have got the Stryker management team here with me. So we have got Spencer Stiles, President and COO, but soon to be CEO, taking over in January. And Preston Wells, the CFO and Vice President of the company. And also Nick Mead in the audience, who runs the IR function. So we are going to do a fireside chat for about 25 minutes, and then we will have breakouts later here through the day. So, guys, I wanted to start off a little bit high level and maybe just talk about some of your strategic goals that were outlined at the Investor Day.
You talk about growing at the high end of MedTech as one main goal, and outperforming your market. So maybe talk about how you are going to achieve that going forward and what gives you the right to win in some of your key markets.
Sure. Thanks, Matt. Thanks for having us. It is super to be here. One of my goals this year was to make sure that I am spending more time with the investment community, and that included a global audience. So it is great to be in London and spending time with some international investors as well. Back to your question, our strategy remains the same. We continue to ensure that we are performing at the high end of our markets that we are playing in. We have confidence in that strategy, and that is our expectation. So if we reflect back on our Investor Day we did about a year ago, that framework has not changed. So that is still the expectation for our organization as we think about sales growth, as we think about the 150 basis points of Op margin expansion on an adjusted basis. That still exists over a three-year period.
That will look a little different each year. We have seen strong cash flow in the business and expect that to continue, targeting about 70%-80% free cash flow each year. So from a framework standpoint, that all still exists, and that is our expectations as we look out to the future.
Preston, I do not know if there is anything you want to add, but No, I mean, you are right in terms of the framework.
The framework stays the same. I think what will change, and I know we will talk a little bit about this, is as Spence takes over, as we think about how we are going to continue that sales growth and how he is going to execute from that standpoint. But, we are just going to focus a little bit on the margin piece, and I know from the standpoint of when we laid out our expectations, the sales growth was a little bit different than what it is right now. And while our margin is somewhat dependent on sales growth, there is so many other areas of opportunity that we have as we continue to focus on operational excellence, as we continue to look at our manufacturing facilities, how do we get more efficient in those spaces.
There is plenty of opportunity for us to continue to drive that 150 basis points in EPS growth, despite what might be a little bit slower sales growth, particularly in 2026.
Great. Maybe two follow-ups on that. Preston, would you start by talking about sort of the shape of the margin expansion? What are some of the key sources? Could you give us some specificity about what to expect sort of this year and next year?
I mean, ideally, it would be great to kind of have it be even throughout, and so that would be the ideal way that we would like to have it. We are in that range right now for 2026. We would like to keep it that way in 2027 and 2028 and make it easy on ourselves from that perspective. But the way it looks is there are a few other things that are happening. We have a lot of things happening with regards to our facilities when we look at product transfers in particular. So how do we bring products that are currently being made outside of Stryker into Stryker? We are able to get cost savings that way. We are looking at a broader plant network optimization where we are looking at low-cost facilities. We have two of those today. We have one in Warsaw, one in Mexico.
How do we continue to drive products to those facilities? We will see bigger chunks of improvement in our gross margin in particular as we go through those types of movements. We also have other areas that we look at across our business. Think about all of the different functional areas that support, like finance, for example, the other functional pieces. We are looking at how do we streamline those parts of our business as well in support of our commercial model, which our commercial model is a little bit more expensive because of the decentralized nature of it. We are looking at how do we get to a more efficient model to support that part of the organization, as well as the gross margin improvements that we are going to see.
We really do expect to see a steady improvement, and there will be some areas that will be larger when we do some of the different plant network activities. Overall, our goal is to have that be a pretty steady cadence for the three-year period.
Great. Spencer, maybe I will ask you, as you take over in the CEO role in January, what stays the same under your leadership as you take over from Kevin? What are some of the new things that you might focus on, and where do you want to put your fingerprints on Stryker?
You bet. I love the question. I will start. You mentioned Kevin. I want to start by thanking Kevin. He has been an incredible leader for our organization, and really invested a lot in my own personal development, things like putting me on an external board, allowing me to sit in committee meetings. Kevin and I sort of joke back and forth that he believes I am much more prepared to step into the CEO role than he was when he joined 14 years ago, and he takes great pride in that development and growth, and just want to thank Kevin for his contributions and all he has done. As we think about the future, there are three big areas that I continue to talk to our organization about.
Number one's accelerating growth, and how do we ensure that we're in the right markets with the right strategies to continue to accelerate our growth across our, second thing I focus on, specialize and deepen our specialization in our business. Accelerating growth, deepening specialization, and the third thing I talk about is simplifying to scale. You heard Preston talk about this as we think about the scale of our organization, this specialized model that we have, the eight operating divisions, 22 different business units. How do we take things where we can scale and modernize and standardize to support that specialization? Preston mentioned some of this. If we think about our plant network, for example, it's broad and vast. There's a way to prioritize that and put more in places that are best cost sites, where we can create more value, we can scale our systems, deploy AI.
That's all an opportunity for that operational improvement. Think about it, growth, profit are sort of the three pillars there that I think about, and probably doubly for our culture, growth times two is a pretty good one. I think that's how I'm thinking about the changes. You'll probably see my fingerprints most early focused on the operating model itself, and so back to this deepening specialization, it's looking at where can we bring more focus and discipline and accountability around the various businesses we have. That is an example of adding, for an example, a third group to focus on a specialized portion of our business, like Neurotechnology and vascular. You'll see that in our operating model evolve and shift. That'll be where I have the earliest impact in the coming months.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
